Available caffeine citrate products not equivalent, warns MHRA

In a letter to healthcare professionals, the MHRA has highlighted that there are two different strengths of caffeine citrate preparation available.

Monitoring of plasma caffeine concentration is recommended during treatment with caffeine citrate | SCIENCE PHOTO LIBRARY
Monitoring of plasma caffeine concentration is recommended during treatment with caffeine citrate | SCIENCE PHOTO LIBRARY

Caffeine citrate is used in neonatal intensive care units to treat primary apnoea in premature infants. Clinicians should note that the strength of caffeine citrate in the branded product Peyona (20mg/ml) is twice that of some generic products currently available (10mg/ml). Prescribers should take careful note of which product is being used to prevent dosing errors.

It is also important to check whether the dose is expressed in terms of the salt (caffeine citrate) or as caffeine base.

Further information:

Drug Safety Update June 2012

View Peyona drug record
View Caffeine citrate drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more